doi:10.19982/j.issn.1000-6621.20210705

Abstract

CLC Number:

R521
R81

Figures/Tables 3

References 13

[1]	World Health Organization. Rapid communication: key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization, 2018.
[2]	Singh A, Prasad R, Balasubramanian V, et al. Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives. HIV AIDS (Auckl), 2020, 12:9-31. doi: 10.2147/HIV.S193059. doi: 10.2147/HIV.S193059
[3]	Sultana ZZ, Hoque FU, Beyene J, et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis, 2021, 21(1):51. doi: 10.1186/s12879-020-05749-2. doi: 10.1186/s12879-020-05749-2 URL
[4]	World Health Organization. Rapid Communication: Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance. Geneva: World Health Organization, 2020.
[5]	World Health Organization. Treatment guidelines for drug-resistant tuberculosis.2016 update. Geneva:World Heahh Organization, 2016.
[6]	Varshney K, Anaele B, Molaei M, et al. Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review. Infect Drug Resist, 2021, 14:5429-5448. doi: 10.2147/IDR.S339972. doi: 10.2147/IDR.S339972 URL
[7]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10):733-749. doi: 10.3760/cma.j.issn.10010939.2019.10.006. doi: 10.3760/cma.j.issn.10010939.2019.10.006
[8]	中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018, 41(1):14-19. doi: 10.3760/cma.j.issn.1001-0939.2018.01.006. doi: 10.3760/cma.j.issn.1001-0939.2018.01.006
[9]	中华医学会结核病学分会, 抗结核新药贝达喹啉临床应用专家共识编写组. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2018, 41(6):461-466. doi: 10.3760/cma.j.issn.1001-0939.2018.06.005. doi: 10.3760/cma.j.issn.1001-0939.2018.06.005
[10]	Padayatchi N, Bionghi N, Osman F, et al. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid. Int J Tuberc Lung Dis, 2020, 24(10):1024-1031. doi: 10.5588/ijtld.20.0048. doi: 10.5588/ijtld.20.0048 pmid: 33126934
[11]	中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2):81-87. doi: 10.3760/cma.j.cn112147-20200714-00805. doi: 10.3760/cma.j.cn112147-20200714-00805
[12]	Lifan Z, Sainan B, Feng S, et al. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis, 2019, 23(12):1293-1307. doi: 10.5588/ijtld.18.0822. doi: 10.5588/ijtld.18.0822 pmid: 31931914
[13]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版). 中国艾滋病性病, 2021, 27(11):1182-1201. doi: 10.13419/j.cnki.aids.2021.11.02. doi: 10.13419/j.cnki.aids.2021.11.02

治疗时间(周)	红细胞 (×10¹²/L)	血红蛋白 (g/L)	调整
0	3.56	149	利奈唑胺600mg/次,口服,每天1次
12	4.42	87	利奈唑胺600mg/次,口服,每周5次
14	1.45	65	停用利奈唑胺
16	2.51	101	利奈唑胺600mg/次,口服,每周5次
40	3.86	79	利奈唑胺300mg/次,口服,每天1次

[1]	Li Min, Yao Yushan, Qiao Haixia, Lei Hong. Association between pulmonary tuberculosis and the gut microbiota: treatment strategies [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 520-526.
[2]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[3]	Song Yunlin, Buzukela Abuduaini, Wang Guirong, Zhang Jiyuan, Lu Xiaobo. Research progresses on the role and mechanism of calcium-binding protein S100A12 and neutrophil extracellular trap formation in lung injury of severe pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 513-519.
[4]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[5]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Li Leilei, Shi Lei, Wang Lin, Li Hongwei, Xu Liran, Pang Yu, Song Yanzheng. Clinical characteristics analysis of HIV-infected cases diagnosed with tuberculosis after surgery due to pulmonary nodules [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 266-273.
[8]	Gong Sheng, Wang Ning, Li Dan, Li Gang, Liu Yu, Jiang Liangshuang, Yao Xiaojun. Comparative study of fluorescence staining method and inflation-deflation method for thoracoscopic pulmonary tuberculosis segmentectomy [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 292-297.
[9]	Shi Yuru, Gu Dejian, Wu Jing, Liu Ting, Qin Linghan, Yue Li, Qi Yingjie. Diagnostic value of probe capture-based targeted next-generation sequencing and metagenomic next-generation sequencing for detecting Mycobacterium tuberculosis in bronchoalveolar lavage fluid [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 305-311.
[10]	Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330.
[11]	Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
[12]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[13]	Gao Li, Chen Shengyu, Zhang Wenqian, Li Dan, Zhang Guoqin. Investigation on ability of conducting tuberculosis surveillance among four types of high-risk population in Tianjin public hospitals [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 195-200.
[14]	Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209.
[15]	Qiu Yong, Quan Zhuo, Qu Rong, Tian Fajun, Li Meng, Wang Gengsheng, Wang Ya, Guo Mingcheng, Gao Qian. Evaluation of different tuberculosis diagnostic tools for detecting patients in a primary-level clinic in rural China: a real-world retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 181-188.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 13

Related Articles 15

Recommended Articles

Metrics

Comments